Clinical relevance of markers of cell proliferation in human lymphoid malignancies: a concise review.
The major advances being made in the understanding of the biology of human lymphoid malignancies have shown these to be a heterogenous group of tumours with respect to a variety of biological markers. The cell proliferative rate, an important determinant of tumor aggressiveness and response to therapy, is one of the biological phenomena currently being investigated in the lymphoid malignancies, particularly in the non-Hodgkin's lymphomas. In this paper we describe the techniques used in the analysis of cell proliferation in the lymphoid malignancies, and review the patterns of cell proliferation found in the various types of these tumours and the clinical relevance of these findings. We indicate that differences in cell proliferative rate are an important determinant of the response of non-Hodgkin's lymphomas to current therapeutic modalities and may explain the paradox that a significant number of reputed unfavorable tumors are now curable. Finally, we suggest that inherent differences in the proliferative rate of the neoplastic cell(s) of the so-called favorable histological types of non-Hodgkin's lymphomas may determine histologic progression as well as therapeutic responsiveness.
D000328:Adult; D002250:Carbon Radioisotopes; D002455:Cell Division; D002648:Child; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005434:Flow Cytometry; D006801:Humans; D008223:Lymphoma / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D013936:Thymidine / Q000378:metabolism; D013937:Thymidine Kinase / Q000378:metabolism; D014316:Tritium
D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm; D014316:Tritium; D013937:Thymidine Kinase; D013936:Thymidine